Inhibition of bacterial and human zinc-metalloproteases by bisphosphonate- and catechol-containing compounds

References

• Artenstein AW, Opal SM. Proprotein convertases in health and disease. N Engl J Med 2011;365:2507–18.
   PubMed Web of Science ®Google Scholar
• Winberg JO, Matrix Proteinases: biological significance in health and disease. In: Karamanos NK, ed. Extracellular matrix: pathobiology and signaling. Berlin: de Gruyter; 2012: 235–238.
   Google Scholar
• De Groef L, Van Hove I, Dekeyster E, et al. MMPs in the neuroretina and optic nerve: modulators of glaucoma pathogenesis and repair? Invest Ophthalmol Vis Sci 2014;55:1953–64.
   PubMed Web of Science ®Google Scholar
• Quiros PM, Langer T, Lopez-Otin C. New roles for mitochondrial proteases in health, ageing and disease. Nat Rev Mol Cell Biol 2015;16:345–59.
   PubMed Web of Science ®Google Scholar
• Ricard-Blum S, Vallet SD. Proteases decode the extracellular matrix cryptome. Biochimie 2016;122:300–13.
   PubMed Web of Science ®Google Scholar
• Rodriguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 2010;1803:39–54.
   PubMed Web of Science ®Google Scholar
• Wolberg AS, Mast AE. Tissue factor and factor VIIa-hemostasis and beyond. Thromb Res 2012;129:S1–S4.
   PubMed Web of Science ®Google Scholar
• Cerda-Costa N, Gomis-Ruth FX. Architecture and function of metallopeptidase catalytic domains. Protein Sci 2014;23:123–44.
   PubMed Web of Science ®Google Scholar
• Gomis-Ruth FX, Botelho TO, Bode W. A standard orientation for metallopeptidases. Biochim Biophys Acta 2012;1824:157–63.
   PubMed Web of Science ®Google Scholar
• Rawlings ND, Barrett AJ, Thomas PD, et al. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Res 2018;46:D624–D632.
   PubMed Web of Science ®Google Scholar
• Hadler-Olsen E, Fadnes B, Sylte I, et al. Regulation of matrix metalloproteinase activity in health and disease. Febs J 2011;278:28–45.
   PubMed Web of Science ®Google Scholar
• Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol 2013;34:2041–51.
   PubMedGoogle Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52–67.
   PubMed Web of Science ®Google Scholar
• Sbardella D, Fasciglione GF, Gioia M, et al. Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes. Mol Aspects Med 2012;33:119–208.
   PubMed Web of Science ®Google Scholar
• Geurts N, Opdenakker G, Van den Steen PE. Van den Steen PE. Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. Pharmacol Ther 2012;133:257–79.
   PubMed Web of Science ®Google Scholar
• Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. Febs J 2011;278:16–27.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov 2014;13:904–27.
   PubMed Web of Science ®Google Scholar
• Yadav L, Puri N, Rastogi V, et al. Matrix metalloproteinases and cancer – roles in threat and therapy. Asian Pac J Cancer Prev 2014;15:1085–91.
   PubMedGoogle Scholar
• Overall CM, Blobel CP. In search of partners: linking extracellular proteases to substrates. Nat Rev Mol Cell Biol 2007;8:245–57.
   PubMed Web of Science ®Google Scholar
• Theocharis AD, Gialeli C, Hascall V, Karmanos N, Extracellular matrix: a functional scaffold. In Karamanos NK, ed. Extracellular matrix: pathobiology and signaling. Berlin: de Gruyter; 2012: 3–19.
   Google Scholar
• Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci 2017;147:1–73.
   PubMed Web of Science ®Google Scholar
• Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657–72.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Wang CY, Werb Z. Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol 2015; 44-46:184–90.
   PubMed Web of Science ®Google Scholar
• Ballok AE, O'Toole GA. Pouring salt on a wound: Pseudomonas aeruginosa virulence factors alter Na + and Cl- flux in the lung. J Bacteriol 2013;195:4013–9.
   PubMed Web of Science ®Google Scholar
• Dubin G. Extracellular proteases of Staphylococcus spp. Biol Chem 2002;383:1075–86.
   PubMed Web of Science ®Google Scholar
• Jensen LM, Walker EJ, Jans DA, Ghildyal R. Proteases of human rhinovirus: role in infection. Methods Mol Biol 2015;1221:129–41.
   PubMedGoogle Scholar
• Maeda H. Role of microbial proteases in pathogenesis. Microbiol Immunol 1996;40:685–99.
   PubMed Web of Science ®Google Scholar
• Matsumoto K. Role of bacterial proteases in pseudomonal and serratial keratitis. Biol Chem 2004;385:1007–16.
   PubMed Web of Science ®Google Scholar
• Shinoda S, Miyoshi S. Proteases produced by vibrios. Biocontrol Sci 2011;16:1–11.
   PubMed Web of Science ®Google Scholar
• Silva-Almeida M, Pereira BAS, Ribeiro-Guimarães ML, Alves CR. Proteinases as virulence factors in Leishmania spp. infection in mammals. Parasit Vectors 2012;5:160.
   PubMed Web of Science ®Google Scholar
• Dickey SW, Cheung GYC, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov 2017;16:457–71.
   PubMed Web of Science ®Google Scholar
• Munguia J, Nizet V. Pharmacological targeting of the host-pathogen interaction: alternatives to classical antibiotics to combat drug-resistant superbugs. Trends Pharmacol Sci 2017;38:473–88.
   PubMed Web of Science ®Google Scholar
• Brotz-Oesterhelt H, Sass P. Bacterial caseinolytic proteases as novel targets for antibacterial treatment. Int J Med Microbiol 2014;304:23–30.
   PubMed Web of Science ®Google Scholar
• Hauser AR, Mecsas J, Moir DT. Beyond antibiotics: new therapeutic approaches for bacterial infections. Clin Infect Dis. 2016;63:89–95.
   PubMed Web of Science ®Google Scholar
• Zambelloni R, Marquez R, Roe AJ. Development of antivirulence compounds: a biochemical review. Chem Biol Drug Des 2015;85:43–55.
   PubMed Web of Science ®Google Scholar
• Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491–4.
   PubMed Web of Science ®Google Scholar
• Woessner Jr., JF, Nagase H, Matrix metalloproteinases and TIMPs. Oxford: Oxford University Press; 2000.
   Google Scholar
• Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 2013;48:222–72.
   PubMed Web of Science ®Google Scholar
• Antoni C, Vera L, Devel L, et al. Crystallization of bi-functional ligand protein complexes. J Struct Biol 2013;182:246–54.
   PubMed Web of Science ®Google Scholar
• Fernandez-Catalan C, Bode W, Huber R, et al. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. Embo J 1998;17:5238–48.
   PubMed Web of Science ®Google Scholar
• Grossman M, Tworowski M, Dym O, et al. The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. Biochemistry 2010;49:6184–92.
   PubMed Web of Science ®Google Scholar
• Nuti E, Cantelmo RA, Gallo C, et al. N-O-isopropyl sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors: hit selection and in vivo antiangiogenic activity. J Med Chem 2015;58:7224–40.
   PubMed Web of Science ®Google Scholar
• Nuti E, Casalini F, Avramova SI, et al. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. J Med Chem 2009;52:4757–73.
   PubMed Web of Science ®Google Scholar
• Nuti E, Casalini F, Avramova SI, et al. Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models. J Med Chem 2010;53:2622–35.
   PubMed Web of Science ®Google Scholar
• Nuti E, Panelli L, Casalini F, et al. Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. J Med Chem 2009;52:6347–61.
   PubMed Web of Science ®Google Scholar
• Rowsell S, Hawtin P, Minshull CA, et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol 2002;319:173–81.
   PubMed Web of Science ®Google Scholar
• Tochowicz A, Maskos K, Huber R, et al. Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol Biol 2007;371:989–1006.
   PubMed Web of Science ®Google Scholar
• Eckhard U, Huesgen PF, Schilling O, et al. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. Matrix Biol 2016;49:37–60.
   PubMed Web of Science ®Google Scholar
• Fabre B, Ramos A, de Pascual-Teresa B. Targeting matrix metalloproteinases: exploring the dynamics of the S1' pocket in the design of selective, small molecule inhibitors. J Med Chem 2014;57:10205–19.
   PubMed Web of Science ®Google Scholar
• Adekoya OA, Sylte I. The thermolysin family (M4) of enzymes: therapeutic and biotechnological potential. Chem Biol Drug Des 2009;73:7–16.
   PubMed Web of Science ®Google Scholar
• Englert L, Biela A, Zayed M, et al. Displacement of disordered water molecules from hydrophobic pocket creates enthalpic signature: binding of phosphonamidate to the S1′-pocket of thermolysin. Biochim Biophys Acta 2010;1800:1192–202.
   PubMed Web of Science ®Google Scholar
• Bever RA, Iglewski BH. Molecular characterization and nucleotide sequence of the Pseudomonas aeruginosa elastase structural gene. J Bacteriol 1988;170:4309–14.
   PubMed Web of Science ®Google Scholar
• Galloway DR. Pseudomonas aeruginosa elastase and elastolysis revisited: recent developments. Mol Microbiol 1991;5:2315–21.
   PubMed Web of Science ®Google Scholar
• Pauptit RA, Karlsson R, Picot D, et al. Crystal structure of neutral protease from Bacillus cereus refined at 3.0 A resolution and comparison with the homologous but more thermostable enzyme thermolysin. J Mol Biol 1988;199:525–37.
   PubMed Web of Science ®Google Scholar
• Thayer MM, Flaherty KM, McKay DB. Three-dimensional structure of the elastase of Pseudomonas aeruginosa at 1.5-A resolution. J Biol Chem 1991;266:2864–71.
   PubMed Web of Science ®Google Scholar
• Banbula A, Potempa J, Travis J, et al. Amino-acid sequence and three-dimensional structure of the Staphylococcus aureus metalloproteinase at 1.72 A resolution. Structure 1998;6:1185–93.
   PubMed Web of Science ®Google Scholar
• Sylte I, Dawadi R, Malla N, et al. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases. PLOS One 2018;13:e0200237.
   PubMed Web of Science ®Google Scholar
• Sjoli S, Nuti E, Camodeca C, et al. Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors. Eur J Med Chem 2016;108:141–53.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Van Wart HE. Kinetics of hydrolysis of dansyl peptide substrates by thermolysin: analysis of fluorescence changes and determination of steady-state kinetic parameters. Biochemistry 1994;33:6508–15.
   PubMed Web of Science ®Google Scholar
• Tauro M, Laghezza A, Loiodice F, et al. Catechol-based matrix metalloproteinase inhibitors with additional antioxidative activity. J Enzyme Inhib Med Chem 2016;31:25–37.
   PubMed Web of Science ®Google Scholar
• Holden HM, Tronrud DE, Monzingo AF, et al. Slow- and fast-binding inhibitors of thermolysin display different modes of binding: crystallographic analysis of extended phosphonamidate transition-state analogues. Biochemistry 1987;26:8542–53.
   PubMed Web of Science ®Google Scholar
• Rubino MT, Agamennone M, Campestre C, et al. Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption. ChemMedChem 2011;6:1258–68.
   PubMed Web of Science ®Google Scholar
• Tauro M, Laghezza A, Loiodice F, et al. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. Bioorg Med Chem 2013;21:6456–65.
   PubMed Web of Science ®Google Scholar
• Malla N, Berg E, Moens U, et al. Biosynthesis of promatrix metalloproteinase-9/chondroitin sulphate proteoglycan heteromer involves a Rottlerin-sensitive pathway. PLOS One 2011;6:e20616.
   PubMed Web of Science ®Google Scholar
• Malla N, Berg E, Uhlin-Hansen L, Winberg JO. Interaction of pro-matrix metalloproteinase-9/proteoglycan heteromer with gelatin and collagen. J Biol Chem 2008;283:13652–65.
   PubMed Web of Science ®Google Scholar
• Dawadi R, Malla N, Hegge B, et al. Molecular interactions stabilizing the promatrix metalloprotease-9. Serglycin Heteromer Int J Mol Sci 2020;21:4205.
   Web of Science ®Google Scholar
• Murphy G, Crabbe T. Gelatinases A and B. Methods Enzymol 1995;248:470–84.
   PubMed Web of Science ®Google Scholar
• Abagyan R, Totrov M, Kuznetsov D. ICM – a new method for protein modeling and design – applications to docking and structure prediction from the distorted native conformation. J Comput Chem 1994;15:488–506.
   Web of Science ®Google Scholar
• Abagyan R, Kufareva I. The flexible pocketome engine for structural chemogenomics. Methods Mol Biol 2009;575:249–79.
   PubMedGoogle Scholar
• Schapira M, Abagyan R, Totrov M. Nuclear hormone receptor targeted virtual screening. J Med Chem 2003;46:3045–59.
   PubMed Web of Science ®Google Scholar
• Tranchant I, Vera L, Czarny B, et al. Halogen bonding controls selectivity of FRET substrate probes for MMP-9. Chem Biol 2014;21:408–13.
   PubMedGoogle Scholar
• Elkins PA, Ho YS, Smith WW, et al. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallogr D Biol Crystallogr 2002;58:1182–92.
   PubMedGoogle Scholar
• Krimmer SG, Cramer J, Betz M, et al. Rational design of thermodynamic and kinetic binding profiles by optimizing surface water networks coating protein-bound ligands. J Med Chem 2016;59:10530–48.
   PubMed Web of Science ®Google Scholar